Updates

Author Details

Joe Pierce

February 24, 2021February 24, 2021
Grants of $4.6M to Support Trials of Cancer Therapy in Early Alzheimer’s

The National Institute of Aging (NIA) and the Alzheimer’s Drug Discovery Foundation (ADDF) have awarded $4.6 million to a team of researchers studying the ... Read more
February 22, 2021February 18, 2021
Dementia Patients Have a Greater Risk of Contracting COVID-19

We’re continually faced with news about COVID-19. It’s impossible to open a newspaper, read a magazine, or watch television without being bombarded with news ... Read more
February 22, 2021February 22, 2021
UsAgainstAlzheimer’s Calls for $289M Hike in Federal Funds for Research

To meet a U.S. goal to effectively treat and prevent Alzheimer’s disease by 2025, patient, caregiver, and advocacy communities are recommending a $289 million ... Read more
February 17, 2021February 17, 2021
HFC to Host CareCon, Virtual Event for Caregivers

A virtual celebrity-studded HFC event aimed at caregivers for Alzheimer’s disease and dementia patients is on tap for Friday, National Caregivers Day. Called HFC CareCon ... Read more
February 15, 2021February 11, 2021
Remaining in the Moment Is the Best Strategy for Alzheimer’s Caregivers

We in the Alzheimer’s community talk a lot about the disappointing and challenging aspects of the disease. One thing we particularly talk about is ... Read more

Subscribe to our mailing list

Get regular updates delivered to your email box.

Author Details

Joe Pierce

Thanks! Please check your email for a confirmation email.

November 8, 2017November 8, 2017

Anavex ‘Cautiously Optimistic’ After Noting Cognitive Improvement in Alzheimer’s Treatment

News

Anavex Life Sciences says its Alzheimer’s drug candidate Anavex 2-73 may have a role in treating the disease. Data from a long-term extension trial, although small, indicated that the therapy improved cognitive and functional measures in patients. According to data ... Read more

Grants of $4.6M to Support Trials of Cancer Therapy in Early Alzheimer’s

Dementia Patients Have a Greater Risk of Contracting COVID-19

UsAgainstAlzheimer’s Calls for $289M Hike in Federal Funds for Research

HFC to Host CareCon, Virtual Event for Caregivers

Remaining in the Moment Is the Best Strategy for Alzheimer’s Caregivers

Oral Simufilam Found to Improve Cognition, Behavior After 6 Months’ Use

Alzheimer’s Association Webinar Tackles Care Disparities for Blacks in US

Seniors Lack Easy Access to Important Health Information

Adira Foundation Arises From Life-altering Accident to Help Those With Chronic Ills

Phase 3 Trial of Therapy for Inflammation, Insulin-sensitivity in Alzheimer’s to Open

Troriluzole Fails to Ease Cognitive Impairments in Phase 2/3 Trial

Subscribe to our mailing list

New Legislation Is a Positive Step Toward Preventing Elder Abuse

FDA Extends Its Aducanumab Review With Decision Expected in June

Patients, Caregivers Urged to Get COVID-19 Vaccines ASAP

COVID-19 Vaccine Should Be a Priority for Alzheimer’s Patients and Caregivers

Non-invasive Neurostimulation Device Wins FDA’s Breakthrough Status

New Technique May Enable Early Diagnosis of Alzheimer’s

Anticipating 2021 When Caregiving Feels Like ‘Groundhog Day’

Axsome Launches AXS-05 Phase 3 Trial for Alzheimer’s-associated Agitation

Donanemab Found to Slow Cognitive, Functional Decline in Early Alzheimer’s

BXCL501 Led to Fast, Safe, Durable Drop in Agitation in Dementia Patients

Support for Research, Patient Care in US 2021 Budget Wins Praise

Phase 3 Trial of Diabetes Treatment in Early Alzheimer’s Patients Planned

Directory Connects Alzheimer’s Caregivers With Valuable Resources

Fujirebio Seeks FDA’s Premarket Approval for Diagnostic Test

Biogen, Eisai Request Approval of Aducanumab for Alzheimer’s in Japan

Choosing Appropriate Gifts for Alzheimer’s Patients and Family Caregivers

Dosing Starts in Athira’s Phase 2 ACT-AD Trial Testing ATH-1017; Enrollment Ongoing

Cortexyme’s COR388 GAIN Trial Advances to Endpoint; Results Expected Late 2021

Finding That Conquering Spirit

Last Patient Finishes ALZT-OP1 Combo Therapy Trial; Results Expected Early 2021

Social Inequalities Found in US Counties With Highest Alzheimer’s Rates Among Blacks, Latinos

IGC Starts Phase 1 Study of Low-dose Cannabinoid in Alzheimer’s Patients

AlzeCure’s Lead Therapy Candidate Entering Phase 1 Testing in Sweden

Don’t Let Alzheimer’s Disease Steal Thanksgiving

Gum Disease Bacteria Found in Most Alzheimer’s Patients in Atuzaginstat Trial

Last Participant Finishes PEGASUS Clinical Trial, Results Expected Next Year

Finding Nursing Home Placement for a Loved One With Alzheimer’s

FDA Clears Neuraly to Begin Phase 2 Trial of NLY01 in Alzheimer’s Patients

FDA Committee Votes Do Not Support Aducanumab as Effective Treatment

National Family Caregivers Month Is a Chance to Spread Happiness

EMA Agrees to Review Biogen, Eisai Request for Aducanumab’s Approval